Lucentis, Diyabetik Makula Ödemi için Amerikan Gıda ve İlaç Dairesi (FDA)’nden onay aldı. (İng)
FDA OKs Lucentis for Diabetic Macular Edema
Roche unit Genentech said Friday the FDA approved Lucentis for diabetic macular edema. Lucentis was first approved by the FDA for treatment of wet age-related macular degeneration in 2006 and for macular edema following retinal vein occlusion in 2010. Lucentis earned $802 million for Roche in the first half of the year, according to Roche’s first half report released in July.